CryoLife (CRY - 900 006) - Schrei des Lebens - 500 Beiträge pro Seite

[Prof.Dr.Schurke]

CryoLife wurde 1984 gegründet und hat seinen sitz in atlanta, usa.

nach eigenen angaben ist das unt. führend in der entwicklung und vermarktung von lebendem menschlichem gewebe, das implantiert werden kann.
diese gewebe werden in der vaskulären (wat is dat?-die kleinen blutgefässe betreffend), der kardiovaskulären (also die herzblutgefässe betreffend) und der orthopädischen Chirurgie eingesetzt, und zwar vornehmlich in den usa und canada.

das produkt BioGlue surgical adhesive, ein chirurgischer Klebstoff ist in den usa nach den hde-regulatorien genehmigt. auch in der europäischen union (ce-markt: produkt-zertifikation)), kanada und australien ist er zugelassen. es wird ergänzend als präparat bei akuten brust-aorta-komplikationen eingesetzt.
zudem stellt das unt. noch Herzklappen her (namentlich SynerGraft). es sind die weltersten auf gewebebasis hergestellten herzklappensubstitute.
ausserdem produziert man herzklappen, die schweinen entnommen wurden und danach für den menschlichen gebrauch
nutzbar gemacht wurden (CryoLife-O´Brien (R)/CryoLife-Ross (R)).

am 18.04.01 erklärte CryoLife, dass man die produktzertifikation in europa für die kommerzielle distribution des modells 700SynerGraft-Lungen-Herzklappe erhalten habe, das auch auf gewebe-basis hergestellt wird.
dies ist schon die sechste zulassung auf dem europäischen markt.

dieses produkt stellt einen gewaltigen fortschritt dar: die technologie bedient sich schweinischer lungen-herzklappen, wobei die schweinischen zellen depopulisiert werden und die zellen des patienten eingesetzt werden.
Folge: die neue menschliche herzklappe entspricht von der struktur und der biodynamik nahezu der herzklappe des empfängers.
so ist es möglich, dass ein heranwachsendes kind bspw. keine weiteren herzklappentransplantationen benötigt, da diese herzklappe mitwächst (!).

zudem arbeitet man noch an der entwicklung zusätzlicher klinischer daten der SynerGraft-Modelle (500 und 700), um im vierten q 01 klinische tests in zusammenarbeit mit der u.s. Food and drug administration durchzuführen.

am 17.04.01 kamen die zahlen für das 1. q 01 heraus:
der umsatz betrug 21,4 millionen usd, 9% mehr als im vorjahresquartal, die gewinne stiegen sogar um 54% auf 2,5 millionen usd im vergleich zum 1.q 00. pro aktie macht das 0,13 cents im vgl. zu 0,09 cents im vorjahresquartal.

der verkauf von BioGlue stieg um 116% im vgl. zum 1.q 00 und um 15% im vgl. zum 4.q 00.
die brutto-margen sind von 54% auf 57% gestiegen.

das unt. hat eine marktkapitalisierung von 504 millionen usd, das kgv beträgt ca. 60. eps für 2000 liegt bei 0.45 usd.
meiner meinung nach ist dies nich zu teuer, wenn man sich das zukünftige marktpotential anschaut. jedoch muss man auch die risiken sehen:
hochinnovatives unt., das auch viel in die forschung investiert und gerade stark expandiert.
dennoch schreibt man gewinne, die konkurrenz hat einen weiten rückstand. umso länger dies anhält, desto grösser der first-mover-advantage von CRY.

Fonds halten 55% der aktien, 53 buys von institutionellen stehen nur 19 sells gegenüber.
das erkennt man auch am chart: vor einem jahr stand die aktie noch bei 11 usd, jetzt steht sie bei 27 usd, spitze war 36 usd. auch in der schwächephase januar/februar 2001 hielt sich der aktienkurs hervorragend im vgl. zu anderen biotech-aktien.
ein klarer aufwärtstrend ist zu erkennen, hohe rel. stärke.
Risiko: sollte cry einmal enttäuschen und springen die institutionellen ab, kommt es zum desaster, vgl. aktuell Cybio.
dennoch: in der letzten zeit sah man oft bei negativem biotech-index-verlauf, dass CryoLife stetig stieg.

in den letzten 3 monaten gab es einen insiderkauf, keinen verkauf. in den letzten 12 monaten dagegen acht verkäufe, was man dem kurs aber nicht ansieht. ich neige eh zu der behauptung, dass insider keineswegs ihr unternehmen besser kennen als aussenstehende, wichtige daten haben sie oftmals nicht im kopf, aber darüber lässt sich streiten.

wer kaufen will, sollte dies auf jeden fall in den usa machen, in d gehen kaum stücke um.
das handelsvolumen liegt bei ca. 100.000 bis 150.000 am tag.

meiner meinung nach handelt es sich um zukunftsträchtige produkte, die in der schnittmenge von biotechnologie und medizintechnik liegen. das künftige marktpotential ist sehr hoch.
jedoch ist das unt. noch klein und birgt viele risiken, eine allzu hohe depotgewichtung ist nicht anzuraten.

schurke

[Prof.Dr.Schurke]

wo ist der beitrag?

[Prof.Dr.Schurke]

.....

[dosto]

geht heut nicht so schnell

oder
zensur?

[Prof.Dr.Schurke]

so, und jetzt nochmal der englische text:

CryoLife, Inc. Receives `CE Mark` Approval for Distribution of Model 700 Synergraft Tissue-Engineered Pulmonary Heart Valves in Europe

ATLANTA, April 18 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of tissue- engineered implantable heart valves, vascular and orthopaedic grafts and surgical adhesives, today announced that it has received a "CE" (product certification) Mark allowing for the commercial distribution of its Model 700 SynerGraft tissue-engineered pulmonary heart valves within the European Community. CryoLife`s Model 700 SynerGraft pulmonary heart valve represents a major development in tissue-engineered replacement biologic devices for repair of damaged or diseased human tissues. The technology incorporates the use of a porcine pulmonary heart valve that has been depopulated of its porcine cells, leaving a collagen matrix that has the potential to repopulate with the recipient`s own cells, providing a bioengineered human heart valve with structure and biodynamics similar to the recipient`s own heart valve. It is anticipated that the tissue-engineered valve will have the capability to grow with the maturing of a child, thus potentially avoiding a series of heart valve replacement procedures.

Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc., said, "The addition of the Model 700 SynerGraft pulmonary heart valve demonstrates the potential for expansion of the SynerGraft technology platform. CryoLife now provides two tissue-engineered heart valves for patients requiring heart valve replacement, the SynerGraft Model 500 aortic valve and the Model 700 pulmonary valve, thus making CryoLife a technology leader in tissue-engineered products. In advanced animal studies, both of these valves have been repopulated with the recipient`s own cells."

The CE Mark for the SynerGraft Model 700 tissue-engineered pulmonary heart valve, granted by Lloyd`s Register Quality Assurance Limited (LRQA) of Coventry, England, represents the sixth CE Mark designation awarded for CryoLife products. CryoLife was awarded its CE Mark for the SynerGraft Model 500 heart valve last year. CryoLife was awarded CE Marks for its stentless porcine aortic and pulmonary heart valves in 1996 and 1998, respectively. CryoLife was also awarded CE Marks in 1998 and 1999 for its BioGlue(R) surgical adhesive for applications in both vascular and pulmonary repairs.

Domestically, CryoLife scientists and regulatory personnel are working on the development of additional SynerGraft Model 500 and 700 clinical data relating to an IDE (Investigational Device Exemption) application to the U.S. Food and Drug Administration to use SynerGraft Model 500 and 700 pulmonary heart valves in human clinical trials. These IDE applications are expected to be made in the fourth quarter of 2001.

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company`s BioGlue surgical adhesive is approved as an adjunct for acute thoracic aortic dissections under HDE regulations in the United States and is CE Marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft heart valve, the world`s first tissue-engineered heart valve replacement and the CryoLife-O`Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are CE Marked for distribution within the European Community. The human heart valves and vascular grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S. under the trade names of CryoValve(R)SG and CryoVein(R)SG, respectively.

Statements made in this release that look forward in time or that express management`s beliefs, expectations or hopes regarding future occurrences are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These future events may not occur when expected, if at all, and are subject to various risks and uncertainties. Such risks and uncertainties include the possibility that SynerGraft heart valves will not repopulate with human recipient cells, or if repopulation does occur, that it will not have the anticipated effects, including without limitation, growing with a maturing child; that future clinical SynerGraft test results will prove less encouraging than current results; that SynerGraft regulatory submissions will not be ready when planned or that anticipated regulatory approvals will not be obtained on a timely basis, if at all; that SynerGraft and SynerGraft SG heart valves will not be accepted by surgeons and other risk factors detailed in the Company`s Securities and Exchange Commission filings, including the Company`s Form 10-K for the year ended December 31, 2000.

For additional information about the company, visit CryoLife`s web site: http://www.cryolife.com . Contact: Roy Vogeltanz

hat denn keiner ne meinung? PDLI, MYGN, MLNM, AFFX, alle schreiben sie verluste, jaja macropore und aap implantate, con.don ..., sagt mal was hier!

[Prof.Dr.Schurke]

CryoLife, Inc. Tissue-Engineering Heart Valve Technology Featured At Cardiovascular Surgical Conference

ATLANTA, May 7 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced the results of two separate medical studies featuring CryoLife`s patented SynerGraft(R) technology. The study results were presented by Ronald C. Elkins, M.D. Chief, Section of Thoracic and Cardiovascular Surgery, University of Oklahoma, Health Sciences Center, Oklahoma City, Oklahoma, a director of and a consultant to CryoLife, Inc., at the Fourth Stentless Bioprostheses (Heart Valve) International Symposium, held in San Diego, California, May 5-7, 2001.

Dr. Elkins reviewed the clinical results of patients implanted with human heart valve allografts processed using CryoLife`s SynerGraft tissue- engineering technology. The SynerGraft technology centers around the removal of antigens from human and animal tissues leaving a collagen matrix that has the potential to then be repopulated, in vivo, with the patient`s own cells. When applied to a heart valve, this creates a replacement tissue structure similar to a native human heart valve with the potential to repopulate with the recipient`s own cells. The SynerGraft tissue-engineered human heart valves, called CryoValve(R)SG, implanted in 66 patients were found to reduce immune responses associated with rejection that are signaled by PRA (panel reactive antibodies) and are often experienced by the recipients of transplanted tissues. These valves may therefore be appropriate for patients who have experienced previous immune response to allograft valve implants and for patients who may have immunodeficiencies.

In a second presentation before the same group, Dr. Elkins reviewed animal studies on the viability of SynerGraft technology-treated porcine heart valves for cellular remodeling. The initial results indicated that the valves implanted in sheep were repopulated with the recipients` cells following implantation.

The SynerGraft heart valve represents the world`s first heart valve replacement technology that depopulates the donor cells leaving a collagen matrix that has the potential to repopulate itself with the recipients` own cells following implantation.

Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc., noted, "Our patented SynerGraft tissue-engineering technology represents a new scientific platform for development of a new family of implantable cardiovascular, vascular and orthopaedic biologic devices that have the potential to reduce negative immune responses and remodel the transplanted tissue with the patient`s own cells, creating functionality similar to the patient`s own tissue structure."

[thediggerman]

hallo!

was geht denn die letzten tage mit cry ab? gibt es irgendwelche neuigkeiten?

wäre sehr dankbar, wenn jemand etwas dazu sagen könnte!

scheint fast so, als ob sie sich aufmacht neue höhen zu erklimmen! vielleicht könnte auch jemand etwas zur technischen situation der aktie sagen!?

thediggerman

[Prof.Dr.Schurke]

cry steht annähernd auf ath, fundamentale news oder adhocs liegen nich vor.
obwohl es in der letzten zeit insiderverkäufe gab, legte cry am fr. ca. 12% zu.

gruss

schurke

[Prof.Dr.Schurke]

CryoLife, Inc. Confirms Dispute

ATLANTA, May 29 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today confirmed that Colorado State University Research Foundation (CSURF) has filed suit against the Company asserting claims with regard to patent and intellectual property matters related to technology CryoLife uses in its SynerGraft(R) processes. The Company has not yet been served with this suit, although it has obtained a copy.

Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc., noted "We do have an agreement with CSURF covering certain technology. We have previously reviewed our obligations under the agreement, consulted with counsel and concluded that CSURF has no rights based on the technology the Company uses in its SynerGraft processes. Our counsel is now reviewing the complaint in detail. Based on the information available to us at this time, we believe the complaint is without merit, and intend to vigorously defend against it. In any event, we do not believe the suit will have a material adverse effect on the Company or its SynerGraft projects."

[Prof.Dr.Schurke]

CryoLife, Inc. Advances Development Of An Injectable Spinal Disc Replacement Device

ATLANTA, May 30 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, presented the results of a biomechanical study on the use of CryoLife`s protein hydrogel device (PHD) technology in the repair of denucleated intervertebral discs at the 14th Annual Meeting for the International Intradiscal Therapy Society, Phoenix, Arizona, May 25-27, 2001. The study was presented by Steven P. Walsh, Ph.D., Director of Biomaterials Technology, CryoLife, Inc.

Denucleation of intervertebral discs is a common treatment for lower back pain that involves the surgical removal of damaged or diseased disc materials resulting in motion destabilization and progressive reduction in disc height. The CryoLife research proposed the use of protein hydrogel (BioDisc(TM)) injected in fluid form into the denucleated disc space that sets up as a pliable support solid to restore disc height and stability while preserving motion. BioDisc employs a unique, minimally invasive delivery system incorporating a dual chamber applicator allowing the surgeon to inject the biomaterial into the void created by the removal of disc materials.

Phase I of the biomechanical study concluded that the application of PHD technology can restore a denucleated interdiscal void to normal height and compressibility, restoring normal spine function and potentially eliminating lower back pain. Phase II animal studies on CryoLife`s BioDisc are currently underway and are expected to be completed by the end of the third quarter of 2001. The results of animal studies of BioDisc will be included in CryoLife`s application for an Investigational Device Exemption (IDE) for human studies expected to be filed in the fourth quarter of 2001.

Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc., noted, "The commercial introduction of BioDisc would represent a major advancement in spinal disc surgical technology and offer orthopedic surgeons, and the more than 320,000 patients in the U.S. that annually undergo spinal disc repair, a potentially more efficient and cost-effective alternative to current disc repair methods." Industry estimates indicate the spinal disc repair market worldwide to be US $1.20 billion in revenues annually

[Prof.Dr.Schurke]

CryoLife, Inc. Advances Its SynerGraft Tissue-Engineering Technology For Transpecies Applications

ATLANTA, June 12 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryo-preserved and tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, presented the results of an animal study, on the use of animal tissues to create A-V (arteriovenous) access grafts in hemodialysis applications using the Company`s patented SynerGraft(R) technology, before the 2001 Joint Annual Meeting of The Society for Vascular Surgery and The American Association for Vascular Surgery, held at the Baltimore Convention Center in Baltimore, Maryland, June 10-13, 2001. The SynerGraft technology centers around the removal of antigens from human and animal tissues leaving a collagen matrix that has the potential to then be repopulated, in vivo, with the patient`s own cells. The canine animal study involved the use of bovine tissues processed with the SynerGraft tissue engineering technology and implanted as A-V access grafts.

The paper was submitted by John H. Matsuura, M.D., F.A.C.S., Assistant Professor of Surgery, Medical College of Georgia, Atlanta, Georgia, and presented by Jeremy D. Ollerenshaw, Ph.D., Director, Vascular Technologies, CryoLife, Inc. Dr. Matsuura is one of CryoLife`s vascular medical advisors. The results of the animal study indicate that the functional parameters of the SynerGraft biologic conduits are favorable for hemodialysis access. Following the six-month animal implants, the SynerGraft A-V access graft demonstrated a lack of infection and improved sealing ability as compared to synthetic grafts.

In 2000 CryoLife began processing human vascular grafts with its SynerGraft technology. The CryoVein(R) SG, which has the potential to re-model itself in vivo, is directed toward patients that have experienced negative reactions with synthetic or tissue access grafts and as a result require replacement grafts that reduce the risk of infection and provide long-term functionality.

Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc., noted, "The successful development of biologic devices that re-model themselves in vivo with the patient`s own cells would be a revolutionary achievement. I believe the SynerGraft technology will provide cardiovascular, vascular and orthopedic surgeons with new alternative treatments for severely ill patients."

As a result of its SynerGraft technology, CryoLife is the first company in the world to produce tissue-engineered vascular grafts and heart valves that have been implanted in humans. The Company`s porcine SynerGraft tissue- engineered replacement heart valves have been awarded the CE (product certification) Mark and are currently in commercial distribution in the European community.

[Prof.Dr.Schurke]

CryoLife, Inc.`s SynerGraft Heart Valve Technology Presented at International Heart Valve Symposium

ATLANTA, June 15 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, presented a comprehensive review of its patented SynerGraft(R) technology in the development of a series of heart valve replacement devices. The SynerGraft technology centers around the removal of antigens from human and animal tissue leaving a collagen matrix that has the potential to be repopulated with the recipient`s own cells. The technology has been utilized to create new tissue-engineered allograft and porcine heart valve replacement devices.

A paper reviewing development of the new heart valve replacement devices was presented by Kirby S. Black, Ph.D., Senior Vice President, Research & Development, CryoLife, Inc., at the Second International Symposium, Tissue Engineering for Heart Valve Substitutes in London, England, June 15, 2001.

CryoLife scientists, utilizing the disciplines of cell biology, biochemistry and protein chemistry, have fostered the development of a tissue- engineering process that allows for the transpecies transplant of tissues without the use of immuno-suppression treatment. The process depopulates or decelluarizes the animal or human tissues using an antigen reduction technology that provides for an implantable, sterile, mechanically stable matrix capable of being repopulated with the recipient`s own cells.

The SynerGraft technology has been successfully used in the development of aortic (Model 500) and pulmonary (Model 700) porcine heart valves that were awarded CE (product certification) Marks. Both SynerGraft Tissue Engineered Heart Valves are currently commercially available within the European community.

[Prof.Dr.Schurke]

hi leute,

cry hat sich sehr stabil gehalten den biotech-index deutlich outperformed und marschiert auf ath (z.zt. bei 33,50 usd)!

überhaupt bleibt festzustellen, dass der biotechindex die neuerlichen kursstürze, vgl. internet und fibre-optic, gut überlebt hat. vom kürzlichen höchststand von ca. 1070 hat man nur 9% abgegeben, der internet-index aber mal eben 25%. aber vorsicht: cry ist sehr riskant!
und auch achtung: insider haben verstärkt verkauft. wollen ma mal schaun, ob das richtig gewesen ist, ich hoffe natürlich nich!

hier die aktuelle meldung: gute testergebnisse der depopulisierten herzklappen.

CryoLife, Inc. Tissue-Engineered Replacement Heart Valve Featured at International Conference

ATLANTA, June 18 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, presented results of studies on CryoLife`s tissue-engineered porcine replacement heart valves processed with the Company`s SynerGraft(R) technology at the First Biennial Meeting of the Society for Heart Valve Disease, held in London, England, June 15-18, 2001. The SynerGraft technology centers around the removal of antigens from animal and human tissue leaving a collagen matrix that has the potential to be repopulated with the recipient`s own cells. The studies were presented by Steven Goldstein, Ph.D., Director, Tissue Technologies, CryoLife, Inc.

The first study concentrated on the functionality of the tissue-engineered porcine heart valves compared to the human counterpart under normal and hypertensive pulsatile flow conditions. Results indicated that the tissue- engineered SynerGraft heart valve matched the normal test parameters of human valves. The study compared both children and adults` human heart valve parameters to the SynerGraft heart valve.

A second study reported on the implantation of SynerGraft processed heart valves into sheep to confirm that the remodeling process had occurred. Upon explant, the results verified that the implanted SynerGraft processed heart valves had remodeled with the recipient`s cells. CryoLife produces two SynerGraft porcine heart valves for distribution in international markets. Both the SynerGraft aortic (Model 500) and pulmonary (Model 700) valves have been awarded the CE (product certification) Marks and are currently in distribution throughout the European community.

Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc., noted, "The successful introduction of our tissue-engineered porcine heart valves in the European Community provides an alternative for cardiovascular surgeons in the international arena to the use of mechanical heart valves, which require a lifetime of anticoagulation drug therapy."


gruss

schurke

[Prof.Dr.Schurke]

Was ist Kryonik?
Kryonik ist ein neulich geprägtes Wort, das sich auf das Verfahren der Konservierung, entweder des ganzen Körpers oder nur des Schädels von Personen bezieht, die gerade legal für tot erklärt wurden, in der Hoffnung auf Wiederbelebung in der Zukunft.

Das Wort wird von Kältetechnik (Cryogenics),die physikalische Wissenschaft sehr niedriger Temperaturen, hergeleitet. Langfristige Kryoniklagerung finded durch Aufbewahrung in flüssigem Stickstoff statt.

Eine umfangreiche Einführung in die Kryonik: "Der Weg nach Dort von Hier (Getting There from Here)", ein Aufsatz von Jim Yount.

[Prof.Dr.Schurke]

Stück Bezeichnung
WKN / Börse Kurs
Datum Kaufsumme Zeit
Datum
Volumen akt.Kurs
akt.Diff.
(Diff. %) heute
Diff.abs.
Diff.% akt.Wert(Eur)
abs. Diff.(Eur)
Diff.% Tools
172,00 APPLIED MICRO CIRCUI
910860 / FSE


25,50
19.03.01 4.386,00 19:35
01.02.02
340 11,90
-0,28
-2,30%
-48,16
-2,30% 2.046,80
-2.339,20
-53,33 %

170,00 CALPINE CORP. DL
902918 / FSE


52,20
19.03.01 8.874,00 19:31
01.02.02
1264 13,45
0,50
3,86%
85,00
3,86% 2.286,50
-6.587,50
-74,23 %

120,00 CHECK POINT SOFTW. T
901638 / FSE


71,70
16.04.01 8.604,00 19:37
01.02.02
8580 41,66
-0,84
-1,98%
-100,80
-1,98% 4.999,20
-3.604,80
-41,90 %

123,00 CIENA CORP. D
905348 / FSE


59,30
19.03.01 7.293,90 19:30
01.02.02
24261 14,10
-1,20
-7,84%
-147,60
-7,84% 1.734,30
-5.559,60
-76,22 %

97,00 CIMA LABS INC. D
899797 / FSE


60,00
19.03.01 5.820,00 18:22
01.02.02
0 30,00
-0,50
-1,64%
-48,50
-1,64% 2.910,00
-2.910,00
-50,00 %

215,00 CORVIS CORP. D
938171 / FSE


9,40
19.03.01 2.021,00 19:38
01.02.02
197 2,30
0,00
0,00%
0,00
0,00% 494,50
-1.526,50
-75,53 %

120,00 CRYOLIFE INC. D
900006 / FSE


31,00
26.04.01 3.720,00 16:01
01.02.02
0 32,00
0,00
0,00%
0,00
0,00% 3.840,00
120,00
3,23 %

135,00 ICOS CORP. D
882008 / FSE


50,30
19.03.01 6.790,50 16:53
01.02.02
545 50,80
0,80
1,60%
108,00
1,60% 6.858,00
67,50
0,99 %

95,00 INTL RECTIFIER
851418 / FSE


43,70
18.06.01 4.151,50 19:35
01.02.02
50 48,10
0,60
1,26%
57,00
1,26% 4.569,50
418,00
10,07 %

84,00 INVITROGEN CORP. D
919313 / FSE


68,00
19.03.01 5.712,00 16:42
01.02.02
160 63,50
0,50
0,79%
42,00
0,79% 5.334,00
-378,00
-6,62 %

76,00 JUNIPER NETWORKS D
923889 / FSE


36,50
05.07.01 2.774,00 19:30
01.02.02
20628 17,40
-0,90
-4,92%
-68,40
-4,92% 1.322,40
-1.451,60
-52,33 %

300,00 MCDATA CORP. A D
625937 / FSE


18,50
19.03.01 5.550,00 19:33
01.02.02
1748 27,50
-1,00
-3,51%
-300,00
-3,51% 8.250,00
2.700,00
48,65 %

67,00 MERCURY INTERACT. DL
890463 / FSE


77,00
17.05.01 5.159,00 10:31
01.02.02
110 44,70
0,00
0,00%
0,00
0,00% 2.994,90
-2.164,10
-41,95 %

435,00 NEOGEN CORP. D
883297 / FSE


11,20
19.03.01 4.872,00 13:39
01.02.02
100 16,40
0,05
0,31%
21,75
0,31% 7.134,00
2.262,00
46,43 %

162,00 NETEGRITY INC. D
917514 / FSE


34,50
19.03.01 5.589,00 19:32
01.02.02
400 18,70
0,50
2,75%
81,00
2,75% 3.029,40
-2.559,60
-45,80 %

318,00 NETWORK APPLIANCE
898173 / FSE


21,10
19.03.01 6.709,80 19:33
01.02.02
6541 21,00
-0,10
-0,47%
-31,80
-0,47% 6.678,00
-31,80
-0,47 %

500,00 OPTICAL COMM. PR. D
579243 / FSE


10,00
19.03.01 5.000,00 09:18
01.02.02
0 3,80
0,10
2,70%
50,00
2,70% 1.900,00
-3.100,00
-62,00 %

Aktienwert in Euro 93.026,70 -300,51
-0,55% 66.381,50
-26.645,20
-28,64%
Barbestand 19,00
Gesamtwert in Euro 66.400,50
Neue Position hinzufügen:

[VASCO@DAGAMA]

.




:O>>>Ja "Prof.Dr.Schurke"


Deiner CryoLife gehts aber heute

kräftig an den Kragen!


Stell dir vor die Leute hätten auf deinen Rat
vom 2.Januar 2002
gehört!?

Dann wären die jetzt alle pleite!



.

[Anderas]

Warum ist heute kein Handel mit CRYOLIFE?